NIIMBL Announces $4.6M to Fund 10 New Biopharmaceutical Manufacturing Projects
NEWARK, Del., June 8, 2021 — The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce funding for 10 new projects in technology, workforce development, and their Global Health Fund initiative, resulting from the Institute’s Project Call 4.1, and with a total value of approximately $4.6M.
NIIMBL eXperience Program Announces 17 Students for 2021 Cohort
CORRECTION 4/22/2021: Update to students’ names and associated institutions.
Newark, Del., April 20, 2021 – The National Institute for Manufacturing Biopharmaceuticals (NIIMBL) announced 17 students selected for their 2021 NIIMBL eXperience Program. The NIIMBL eXperience is offered to African American/Black, Latinx, and Native American college freshman and sophomores students from Historically Black Colleges and Universities (HBCUs) and NIIMBL member institutions and provides real-world insight into career options in the growing biopharmaceutical industry.
NIIMBL Welcomes Dr. Gene Schaefer as Senior Fellow
Newark, Del., April 13, 2021 – The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce that Dr. Gene Schaefer has joined the Institute as NIIMBL Senior Fellow, effective April 5, 2021. Dr. Schaefer joins NIIMBL with over 35 years of experience in the biopharmaceutical field ranging from early-stage process development to commercial product support for protein therapeutics.
ARP Response 2021
American Rescue Plan (ARP) Response
Submissions Due Friday, April 9, 2021 by 5:00 pm ET
Announced: March 30, 2021
NIIMBL Leads Joint Publication on End-to-End Process Intensification Program
The NIIMBL leadership along with colleagues from the government and the biopharma industry authored a recent publication in Biotechnology & Bioengineering describing NIIMBL’s ambitious 10-year collaborative program to invent, design, demonstrate, and support the commercialization of integrated biopharmaceutical manufacturing technology intended to transform the industry.
NIIMBL Release 2019-2020 Annual Report
Download the March 2019 – February 2020 Annual Report here.
This year’s report highlights how our community of more than 150 members is advancing the biopharmaceutical industry by developing new technologies and strengthening the talent pipeline.
NIIMBL Announces Nine Project Recipients of $8.9M in Pandemic Response Efforts
NEWARK, DE. — Today, the National Institute for Innovation in Manufacturing Biopharmacueticals (NIIMBL) announces that they have identified nine projects to allocate approximately $8.9 million from the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) award received in May 2020 towards the support of the nation’s response to the COVID-19 pandemic.
NIIMBL is Awarded $8.9M from NIST for Pandemic Response
NEWARK, DE. — Today, the National Institute for Innovation in Biopharmaceutical Manufacturing (NIIMBL) announces that they have received $8.9 million from the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST). This award will fund high-impact projects that will support the nation’s response to the COVID-19 pandemic. The funding is part of the first round of funding made available to NIST through the Coronavirus Aid, Relief, and Economic Security (CARES) Act.
NIIMBL Announces $10M in New Project Funding
NEWARK, Del., May 19, 2020 — The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce funding for 14 new projects in technology, workforce development, and in their Global Health Fund initiative, resulting from the Institute’s Project Call 3.1, and with a total value of approximately $10M.
NIIMBL Names John Erickson as Acting Chief Technology Officer
NEWARK, Del., May 12, 2020 — The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced today that John Erickson, NIIMBL Senior Fellow, is named Acting Chief Technology Officer (CTO). Current CTO, Dr. Ruben Carbonell will be stepping out of this role but will continue to support NIIMBL as Senior Technology Strategist.
Demand will be higher than anticipated for biopharmaceutical manufacturing talent!
Opinion Piece by John Balchunas
March 31, 2020
NIIMBL and FDA Sign Agreement to Support Innovation in Biopharma Manufacturing
Newark, Del., July 31, 2019 – The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced that the University of Delaware, on behalf of NIIMBL, has entered into a Collaborative Research and Development Agreement (CRADA) with the Food and Drug Administration (FDA). Effective July 15, 2019, the FDA and NIIMBL will have the ability to collaborate in a pre-competitive environment to strengthen research, innovation, training, and collaboration in the biopharmaceutical manufacturing industry.